GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » YoY EPS Growth

Gelesis Holdings (Gelesis Holdings) YoY EPS Growth : 41.18% (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Gelesis Holdings's YoY EPS Growth for the quarter that ended in Jun. 2023 was 41.18%.

Gelesis Holdings's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $-0.10.


Gelesis Holdings YoY EPS Growth Historical Data

The historical data trend for Gelesis Holdings's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings YoY EPS Growth Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
YoY EPS Growth
- 95.90

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.09 97.88 -192.70 90.00 41.18

Gelesis Holdings YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Gelesis Holdings's YoY EPS Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EPS Growth (A: Dec. 2022 )
=(Earnings per Share (Diluted) (A: Dec. 2022 )-Earnings per Share (Diluted) (A: Dec. 2021 ))/ | Earnings per Share (Diluted) (A: Dec. 2021 ) |
=(-1.35--32.89)/ | -32.89 |
=95.90 %

Gelesis Holdings's YoY EPS Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EPS Growth (Q: Jun. 2023 )
=(Earnings per Share (Diluted) (Q: Jun. 2023 )-Earnings per Share (Diluted) (Q: Jun. 2022 )) / | Earnings per Share (Diluted) (Q: Jun. 2022 )) |
=(-0.1--0.17)/ | -0.17 |
=41.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gelesis Holdings YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Gelesis Holdings (Gelesis Holdings) Business Description

Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
Raju S Kucherlapati director 77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc 10 percent owner 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd 10 percent owner SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino officer: Lead Project Scientist C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks director GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass officer: Chief Op. & Comm. Officer GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette officer: Chief Scientific Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider officer: Chief Medical Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher director 2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech 10 percent owner 6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc 10 percent owner 142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar director, officer: President & CEO C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms 10 percent owner C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510

Gelesis Holdings (Gelesis Holdings) Headlines

From GuruFocus

Gelesis to Report Full Year 2021 Financial Results on March 24, 2022

By Business Wire Business Wire 03-17-2022